HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (1) Citing Articles via Google Scholar Google Scholar Articles by Lempiäinen, A. Articles by Stenman, U.-H. Search for Related Content PubMed PubMed Citation Articles by Lempiäinen, A. Articles by Stenman, U.-H. Related Collections Cancer Diagnostics (since 2002)

Increased Human Chorionic Gonadotropin Due to Hypogonadism after Treatment of a Testicular Seminoma

¹ Departments of Clinical Chemistry and ² Oncology, Helsinki University Central Hospital, Helsinki University, Helsinki, Finland

^aAddress correspondence to this author at: Ulf-Håkan Stenman, Helsinki University Central Hospital, Biomedicum Helsinki, Rm. A423a, Haartmaninkatu 8, P.O. Box 700, FIN-00029 Helsinki, Finland. Fax 358-9-47171737; e-mail ulf-hakan.stenman@hus.fi.

The first 20% of the full text of this article appears below.

To the Editor:

Alfa-fetoprotein (AFP) and serum human chorionic gonadotropin (hCG) are reliable markers of testicular cancer, and treatment of a relapse is often initiated on the basis of marker increase alone. Slightly increased hCG concentrations have occasionally been misinterpreted to indicate a relapse, leading to inappropriate chemotherapy (1). We describe a seminoma patient in whom a relapse was suspected 10 years after therapy because the patient had increased hCG concentrations found to be caused by hypogonadism-induced pituitary hCG secretion.

A 27-year-old man underwent left radical orchiectomy and adjuvant radiotherapy for stage I testicular seminoma in the early 1990s at Helsinki University Central Hospital. The patient had a preoperative serum hCG of 0.5 IU/L (upper reference limit 0.7 IU/L) and AFP <1 IU/L (upper reference limit 9 IU/L). Atrophy of the nonmalignant testicle was suspected on the basis of preoperative ultrasound findings, but the serum testosterone concentration, 10.2 nmol/L, was within the reference interval (10–38 nmol/L), whereas follicle-stimulating hormone (FSH) concentration was increased, at 28 . . . [Full Text of this Article]

The following articles in journals at HighWire Press have cited this article:

				C. M. Sturgeon, M. J. Duffy, U.-H. Stenman, H. Lilja, N. Brunner, D. W. Chan, R. Babaian, R. C. Bast Jr., B. Dowell, F. J. Esteva, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers Clin. Chem., December 1, 2008; 54(12): e11 - e79. [Abstract] [Full Text] [PDF]

				A. Lempiainen, U.-H. Stenman, C. Blomqvist, and K. Hotakainen Free {beta}-Subunit of Human Chorionic Gonadotropin in Serum Is a Diagnostically Sensitive Marker of Seminomatous Testicular Cancer Clin. Chem., November 1, 2008; 54(11): 1840 - 1843. [Abstract] [Full Text] [PDF]

				B. E.P.B. Ballieux, N. I. Weijl, H. Gelderblom, J. van Pelt, and S. Osanto False-Positive Serum Human Chorionic Gonadotropin (hCG) in a Male Patient with a Malignant Germ Cell Tumor of the Testis: A Case Report and Review of the Literature Oncologist, November 1, 2008; 13(11): 1149 - 1154. [Abstract] [Full Text] [PDF]

				U.-H. Stenman Commentary Clin. Chem., January 1, 2008; 54(1): 213 - 214. [Full Text] [PDF]